Hailing Lu
Tumor Vaccine Group
University of Washington
Box 358050
Seattle
USA
Name/email consistency: high
- Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Lu, H., Ladd, J., Feng, Z., Wu, M., Goodell, V., Pitteri, S.J., Li, C.I., Prentice, R., Hanash, S.M., Disis, M.L. Cancer. Prev. Res. (Phila) (2012)
- Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. Lu, H., Wagner, W.M., Gad, E., Yang, Y., Duan, H., Amon, L.M., Van Denend, N., Larson, E.R., Chang, A., Tufvesson, H., Disis, M.L. J. Immunol. (2010)
- Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. Lu, H., Goodell, V., Disis, M.L. J. Proteome Res. (2008)
- Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Lu, H., Goodell, V., Disis, M.L. Expert Opin. Ther. Targets (2007)
- The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Lu, H., Knutson, K.L., Gad, E., Disis, M.L. Cancer Res. (2006)